- Home
- HURN vs ZLAB Comparison
HURN vs ZLAB Comparison
Compare HURN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- ZLAB
- Stock Information
- Founded
- HURN 2002
- ZLAB 2013
- Country
- HURN United States
- ZLAB China
- Employees
- HURN N/A
- ZLAB N/A
- Industry
- HURN Professional Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- ZLAB Health Care
- Exchange
- HURN Nasdaq
- ZLAB Nasdaq
- Market Cap
- HURN 2.6B
- ZLAB 3.6B
- IPO Year
- HURN 2004
- ZLAB 2017
- Fundamental
- Price
- HURN $139.61
- ZLAB $36.40
- Analyst Decision
- HURN Strong Buy
- ZLAB Buy
- Analyst Count
- HURN 4
- ZLAB 5
- Target Price
- HURN $170.75
- ZLAB $54.28
- AVG Volume (30 Days)
- HURN 187.3K
- ZLAB 886.5K
- Earning Date
- HURN 07-29-2025
- ZLAB 08-05-2025
- Dividend Yield
- HURN N/A
- ZLAB N/A
- EPS Growth
- HURN 92.74
- ZLAB N/A
- EPS
- HURN 6.67
- ZLAB N/A
- Revenue
- HURN $1,525,814,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- HURN $11.50
- ZLAB $44.07
- Revenue Next Year
- HURN $7.48
- ZLAB $49.13
- P/E Ratio
- HURN $20.95
- ZLAB N/A
- Revenue Growth
- HURN 8.98
- ZLAB 43.72
- 52 Week Low
- HURN $96.45
- ZLAB $16.01
- 52 Week High
- HURN $155.00
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- HURN 50.92
- ZLAB 52.67
- Support Level
- HURN $135.66
- ZLAB $34.79
- Resistance Level
- HURN $140.77
- ZLAB $36.73
- Average True Range (ATR)
- HURN 3.19
- ZLAB 1.23
- MACD
- HURN 0.76
- ZLAB -0.46
- Stochastic Oscillator
- HURN 81.39
- ZLAB 25.91
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.